Last reviewed · How we verify
Vancomycin IV
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption.
Vancomycin inhibits bacterial cell wall synthesis by binding to D-Ala-D-Ala peptidoglycan precursors, preventing cross-linking and causing cell wall disruption. Used for Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA), Bacterial endocarditis, Clostridium difficile-associated diarrhea and colitis.
At a glance
| Generic name | Vancomycin IV |
|---|---|
| Sponsor | Debiopharm International SA |
| Drug class | Glycopeptide antibiotic |
| Target | D-Ala-D-Ala peptidoglycan precursor |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Vancomycin is a glycopeptide antibiotic that binds to the D-alanyl-D-alanine terminus of peptidoglycan precursors in bacterial cell walls, blocking the cross-linking reactions catalyzed by transpeptidases. This prevents proper cell wall formation and integrity, leading to bacterial cell lysis and death. It is bactericidal and particularly effective against gram-positive organisms.
Approved indications
- Serious or life-threatening infections caused by susceptible strains of methicillin-resistant Staphylococcus aureus (MRSA)
- Bacterial endocarditis
- Clostridium difficile-associated diarrhea and colitis
- Staphylococcal enterocolitis
- Gram-positive infections in penicillin-allergic patients
Common side effects
- Nephrotoxicity (acute kidney injury)
- Ototoxicity (hearing loss)
- Red man syndrome (flushing, pruritus, erythema)
- Phlebitis at infusion site
- Fever
- Chills
- Nausea
Key clinical trials
- IO Vancomycin Spine (PHASE2, PHASE3)
- Real-component vs All-cement Articulating Spacers for Periprosthetic Knee Infection (NA)
- A Phase 1/2 Study to Evaluate the Safety, PK and Efficacy of TNP-2092 Administered Via IA Injection in PJI Participants (PHASE1, PHASE2)
- Daptomycin vs. Vancomycin for the Treatment of Methicillin Resistant S. Aureus Bacteremia (PHASE4)
- Nivolumab (Anti-PD1), Tadalafil and Oral Vancomycin in People With Refractory Primary Hepatocellular Carcinoma or Liver Dominant Metastatic Cancer From Colorectal or Pancreatic Cancers (PHASE2)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Staphylococcus (PHASE3)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (PHASE3)
- Clindamycin as an Alternative to Vancomycin in Patients Undergoing Aortic Cardiac Surgery With Extracorporeal Circulation (ECC) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vancomycin IV CI brief — competitive landscape report
- Vancomycin IV updates RSS · CI watch RSS
- Debiopharm International SA portfolio CI